<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987489</url>
  </required_header>
  <id_info>
    <org_study_id>4202-HEM-201</org_study_id>
    <nct_id>NCT04987489</nct_id>
  </id_info>
  <brief_title>A Study of FT-4202 in Patients With Thalassemia or Sickle Cell Disease</brief_title>
  <official_title>A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat (FT-4202) in Patients With Thalassemia or Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forma Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forma Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of&#xD;
      etavopivat (FT-4202) in patients with thalassemia or sickle cell disease and test how well&#xD;
      etavopivat works to lower the number of red blood cell transfusions required and increase&#xD;
      hemoglobin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Etavopivat is a potent, selective, orally bioavailable, small-molecule activator of pyruvate&#xD;
      kinase red blood cell (PKR) being developed by Forma Therapeutics, Inc and is intended for&#xD;
      use as a treatment for patients with sickle cell disease (SCD) or other inherited&#xD;
      hemoglobinopathies or refractory anemias. This study is a multicenter, Phase 2, open-label,&#xD;
      multiple-cohort study examining the safety and efficacy of etavopivat for the treatment of&#xD;
      patients, age 12 to 65 years, with SCD or thalassemia. Three treatment cohorts based on the&#xD;
      patients hemoglobinopathy (SCD or thalassemia) and transfusion requirements will be&#xD;
      evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohorts A: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts B: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort C: Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Reduction in red blood cell transfusions over 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Reduction in red blood cell transfusions over 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Reduction in red blood cell transfusions over 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Reduction in red blood cell transfusions over 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Reduction in red blood cell transfusions over 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Reduction in red blood cell transfusions over 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort C: Hemoglobin response rate at Week 24 (increase of ≥ 1.0 g/dL from baseline).</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort C: Hemoglobin response rate at Week 48 (increase of ≥ 1.0 g/dL from baseline).</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin over 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin over 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin over 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum ferritin levels at 12 weeks versus baseline.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum ferritin levels at 24 weeks versus baseline.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum ferritin levels at 48 weeks versus baseline.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver iron concentration at 48 weeks versus baseline</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Etavopivat 400 mg daily - SCD with transfusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with sickle cell disease on chronic red blood cell transfusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etavopivat 400 mg daily - Thalassemia with transfusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with thalassemia on chronic red blood cell transfusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etavopivat 400 mg daily - Thalassemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with thalassemia not on chronic red blood cell transfusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etavopivat tablets</intervention_name>
    <description>Etavopivat 400 mg once daily</description>
    <arm_group_label>Etavopivat 400 mg daily - SCD with transfusions</arm_group_label>
    <arm_group_label>Etavopivat 400 mg daily - Thalassemia</arm_group_label>
    <arm_group_label>Etavopivat 400 mg daily - Thalassemia with transfusions</arm_group_label>
    <other_name>FT-4202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of consent&#xD;
&#xD;
          -  Female patients of childbearing potential must use highly effective methods of&#xD;
             contraception, male patients are willing to use barrier methods of contraception&#xD;
&#xD;
        Cohort A (Sickle Cell Disease Transfusion Cohort)&#xD;
&#xD;
          -  Confirmed diagnosis of sickle cell disease&#xD;
&#xD;
          -  Chronically red blood cell transfused for primary stroke prevention or due to previous&#xD;
             stroke. Chronic red blood cell transfusion is defined as: ≥ 6 red blood cell units in&#xD;
             the previous 24 weeks before the first dose of study treatment and no transfusion-free&#xD;
             period for &gt; 35 days during that period&#xD;
&#xD;
          -  Receiving chronic red blood cell transfusion by straight transfusions&#xD;
&#xD;
          -  At least 24 months of chronic monthly red blood cell transfusions for primary stroke&#xD;
             prevention or treatment of primary stroke (initial completed overt clinical stroke&#xD;
             with document infarction on brain computed tomography [CT] or magnetic resonance&#xD;
             imaging [MRI])&#xD;
&#xD;
          -  On iron chelation therapy for &gt; 3 months prior to enrollment&#xD;
&#xD;
          -  Documented adequate monthly transfusions with average HbS ≤ 45% (the upper limit of&#xD;
             the established academic community standard) for the previous 12 weeks of red blood&#xD;
             cell transfusions before the first dose of study treatment&#xD;
&#xD;
        Cohort B (Thalassemia Transfusion Cohort)&#xD;
&#xD;
          -  Documented diagnosis of β-thalassemia, Hemoglobin E/ β-thalassemia or Hemoglobin H&#xD;
             (α-thalassemia)&#xD;
&#xD;
          -  Chronically transfused, defined as: ≥ 6 red blood cell units in the previous 24 weeks&#xD;
             before the first dose of study treatment and no transfusion-free period for &gt; 35 days&#xD;
             during that period&#xD;
&#xD;
          -  On iron chelation therapy for &gt; 3 months prior to enrollment&#xD;
&#xD;
        Cohort C (Thalassemia Non-transfused Cohort)&#xD;
&#xD;
          -  Documented diagnosis of β-thalassemia, Hemoglobin E/ β-thalassemia or Hemoglobin H&#xD;
             (α-thalassemia)&#xD;
&#xD;
          -  Hemoglobin ≤ 10 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is breast feeding or pregnant&#xD;
&#xD;
          -  Hepatic dysfunction characterized by:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 4.0 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Direct bilirubin &gt; 3.0 × ULN&#xD;
&#xD;
               -  History of cirrhosis&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Severe renal dysfunction or on chronic dialysis&#xD;
&#xD;
          -  History of malignancy within the past 2 years prior to treatment Day 1 requiring&#xD;
             systemic chemotherapy and/or radiation.&#xD;
&#xD;
               -  Patients with malignancy considered surgically cured are eligible (eg, non-&#xD;
                  melanoma skin cancer, cancer of the cervix in-situ, ductal carcinoma in situ&#xD;
                  [Stage 1], Grade 1 endometrial cancer)&#xD;
&#xD;
          -  History of unstable or deteriorating cardiac or pulmonary disease within 6 months&#xD;
             prior to consent including but not limited to the following:&#xD;
&#xD;
               -  Unstable angina pectoris or myocardial infarction or elective coronary&#xD;
                  intervention&#xD;
&#xD;
               -  Congestive heart failure requiring hospitalization&#xD;
&#xD;
               -  Uncontrolled clinically significant arrhythmias&#xD;
&#xD;
               -  Symptomatic pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Von Potter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Forma Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Forma Therapeutics</last_name>
    <phone>617-679-1970</phone>
    <email>medicalinformation@formatherapeutics.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCD</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell</keyword>
  <keyword>anemia</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>hemolytic</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>vaso-occlusive crisis</keyword>
  <keyword>VOC</keyword>
  <keyword>vaso-occlusive events</keyword>
  <keyword>sickle cell crisis</keyword>
  <keyword>pain crisis</keyword>
  <keyword>pain episode</keyword>
  <keyword>congenital anemia</keyword>
  <keyword>hemolytic anemia</keyword>
  <keyword>hematologic disease</keyword>
  <keyword>hemoglobinopathy</keyword>
  <keyword>hemoglobinopathies</keyword>
  <keyword>genetic disease</keyword>
  <keyword>inborn disease</keyword>
  <keyword>sickle cell trait</keyword>
  <keyword>pyruvate kinase</keyword>
  <keyword>PKR</keyword>
  <keyword>thalassemia</keyword>
  <keyword>beta-thalassemia</keyword>
  <keyword>alpha-thalassemia</keyword>
  <keyword>transfusions</keyword>
  <keyword>hemoglobin H</keyword>
  <keyword>transfusion</keyword>
  <keyword>transfusion-dependent</keyword>
  <keyword>non-transfusion dependent</keyword>
  <keyword>hemoglobin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

